NCT04389112

Brief Summary

Skin carcinomas are the most frequent cancers in the world, including basal cell carcinomas and cutaneous squamous cell carcinoma (cSCCs), with more than 60.000 new annual cases in France. Their incidence increases mainly due to ultraviolet (UV) exposure and population ageing. Then from 1994 to 2006, the incidence of cSCC has increased by 300%. CSCCs typically manifests as a spectrum from a precursor actinic keratosis (AK) - possible spontaneous regression at this stage- to in situ cSCC invasive cSCC and finally metastatic cSCC.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 28, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 31, 2020

Completed
2 months until next milestone

First Posted

Study publicly available on registry

May 15, 2020

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

November 23, 2022

Status Verified

November 1, 2022

Enrollment Period

2.8 years

First QC Date

March 31, 2020

Last Update Submit

November 22, 2022

Conditions

Keywords

Actinic keratosismitochondriametabolism

Outcome Measures

Primary Outcomes (2)

  • Proportion of patients who have a glycolysis profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))

    Metabolic profiling of different stages of carcinogenesis: glycolysis, oxidative phosphorylation

    Day 1

  • Proportion of patients who have an oxidative profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))

    Metabolic profiling of different stages of carcinogenesis: glycolysis, oxidative phosphorylation

    Day 1

Secondary Outcomes (5)

  • Evaluation of skin differentiation markers

    Day 1

  • Evaluation of cSCC aggressiveness markers

    Day 1

  • Evaluation of skin apoptotic markers

    Day 1

  • Evaluation of mitochondrial metabolism on skin biopsies

    Day 1

  • Evaluation of cancer proliferative features on skin biopsies

    Day 1

Study Arms (4)

Patients with actinic keratoses

EXPERIMENTAL
Other: biopsy

patients with squamous cell carcinoma in situ

EXPERIMENTAL
Other: biopsy

patients with squamous cell carcinomas

EXPERIMENTAL
Other: biopsy

patient with invasive metastates

EXPERIMENTAL
Other: biopsy

Interventions

biopsyOTHER

Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.

Patients with actinic keratosespatient with invasive metastatespatients with squamous cell carcinoma in situpatients with squamous cell carcinomas

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Every patient with suspected lesion :
  • AK,
  • in situ cSCC,
  • infiltrative cSSC
  • cSCC with recurrent disease
  • cSCC with cutaneous metastases.
  • Patients 18 years of age or older,
  • Patients with suspected AK or BCC lesions (in situ, infiltrating or metastatic),
  • Patient able to sign a consent form,
  • Patient affiliated with a Social Security system.

You may not qualify if:

  • Prior systemic treatment such as checkpoint inhibitors or chemotherapy.
  • Patients with cSCC or AK localized on visible zone of the face or folds

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Saint-André - CHU de Bordeaux

Bordeaux, 33000, France

RECRUITING

Related Publications (4)

  • Obre E, Rossignol R. Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. Int J Biochem Cell Biol. 2015 Feb;59:167-81. doi: 10.1016/j.biocel.2014.12.008. Epub 2014 Dec 24.

    PMID: 25542180BACKGROUND
  • Hosseini M, Dousset L, Mahfouf W, Serrano-Sanchez M, Redonnet-Vernhet I, Mesli S, Kasraian Z, Obre E, Bonneu M, Claverol S, Vlaski M, Ivanovic Z, Rachidi W, Douki T, Taieb A, Bouzier-Sore AK, Rossignol R, Rezvani HR. Energy Metabolism Rewiring Precedes UVB-Induced Primary Skin Tumor Formation. Cell Rep. 2018 Jun 19;23(12):3621-3634. doi: 10.1016/j.celrep.2018.05.060.

    PMID: 29925003BACKGROUND
  • Hosseini M, Dousset L, Michon P, Mahfouf W, Muzotte E, Bergeron V, Bortolotto D, Rossignol R, Moisan F, Taieb A, Bouzier-Sore AK, Rezvani HR. UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis. Oncogenesis. 2019 Sep 24;8(10):52. doi: 10.1038/s41389-019-0161-z.

    PMID: 31551419BACKGROUND
  • Mahfouf W, Hosseini M, Muzotte E, Serrano-Sanchez M, Dousset L, Moisan F, Rachidi W, Taieb A, Rudolf J, Rezvani HR. Loss of Epidermal HIF-1alpha Blocks UVB-Induced Tumorigenesis by Affecting DNA Repair Capacity and Oxidative Stress. J Invest Dermatol. 2019 Sep;139(9):2016-2028.e7. doi: 10.1016/j.jid.2019.01.035. Epub 2019 Mar 13.

    PMID: 30878676BACKGROUND

MeSH Terms

Conditions

Carcinoma, Basal CellKeratosis, Actinic

Interventions

Biopsy

Condition Hierarchy (Ancestors)

CarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms, Basal CellPrecancerous ConditionsKeratosisSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

CytodiagnosisCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisSpecimen HandlingDiagnostic Techniques, SurgicalSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Marie BEYLOT-BARRY, MD, PhD

    University Hospital, Bordeaux

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 31, 2020

First Posted

May 15, 2020

Study Start

February 28, 2020

Primary Completion

December 31, 2022

Study Completion

December 31, 2022

Last Updated

November 23, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations